Atumelnant CRN04894 (ACTH antagonist)

June 02, 2026 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced six abstracts (including multiple oral presentations) to be presented at the Endocrine Society’s ENDO 2026 meeting (June 13–16, 2026; Chicago).

Three presentations focus on PALSONIFY™ (paltusotine), Crinetics’ once-daily oral SST2 agonist approved in the U.S. and EU for adults with acromegaly. An oral session will report up to two years of efficacy plus pooled safety from the PATHFNDR-1 and PATHFNDR-2 open-label extension studies, intended to support long-term safety/efficacy and “best-in-class” positioning. Additional posters cover long-term use of paltusotine with cabergoline (ACROBAT Advance) and real-world biochemical control in acromegaly using U.S. claims and laboratory data to highlight unmet need and management optimization.

Three presentations cover atumelnant (CRN04894), an investigational once-daily oral ACTH receptor (MC2R) antagonist, including full Phase 2 results in congenital adrenal hyperplasia (including glucocorticoid dose lowering with sustained androgen reduction), interim Phase 1b/2a data in ACTH-dependent Cushing’s syndrome, and model-informed dose selection supporting Phase 3 planning. Clinically, the program targets improved oral options for ACTH-excess disorders; commercially, the conference updates support lifecycle and pipeline value.